Search

Your search keyword '"Thach, Allen"' showing total 32 results
Start Over Author "Thach, Allen" Language english
32 results on '"Thach, Allen"'

1. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Author

Aaberg, Thomas, Jr., Abbey, Ashkan, Abdulaeva, Elmira, Abengoechea, Santiago, Abraham, Prema, Ach, Thomas, Adams, Serrhel, Adan Civera, Alfredo, Adrean, Sean, Agostini, Hansjurgen, Alam, Suhail, Alezzandrini, Arturo, Alfaro, Virgil, Aliseda, Daniel, Almony, Arghavan, Amat, Pedro, Amini, Payam, Antoszyk, Andrew, Arias, Luis, Asaria, Riaz, Avila, Marcos, Awh, Carl C., Bafalluy, Joaquin, Baker, Carl, Bandello, Francesco, Barakat, Mark, Barraza, Karen, Bator, Gyorgy, Baumal, Caroline, Belfort, Rubens, Jr., Bergstrom, Chris, Bertolucci, George, Bochow, Thomas, Bolz, Matthias, Borcz, Emilia, Bordon, Arnaldo, Boyer, David, Bratko, Galina, Brent, Michael, Brown, Jamin, Brown, David M., Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Burton, Ben, Busquets, Miguel, Cabrera, Francisco, Cagini, Carlo, Calzada, Jorge, Campochiaro, Peter, Carlson, John, Castellarin, Alessandro, Cava, Carlos, Chaikitmongkol, Voraporn, Chan, Clement, Chang, Emmanuel, Chang, Jonathan, Chang, Andrew, Charles, Steve, Chaudhry, Nauman, Chee, Caroline, Chen, Judy, Chen, Fred, Chen, Shih-Jen, Cheong-Leen, Richard, Chiang, Allen, Chittum, Mark, Chow, David, Connolly, Brian, Cornut, Pierre Loic, Csaky, Karl, Danzig, Carl, Das, Arup, Daskalov, Vesselin, Desco, Carmen, Dessouki, Amr, Dickinson, John, Do, Brian, Dollin, Michael, Dugel, Pravin, Dusova, Jaroslava, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Ernest, Jan, Escobar, Joan Josep, Esposti, Simona, Eter, Nicole, Falk, Naomi, Farkas, Andrej, Feiner, Leonard, Feltgen, Nicolas, Fernandez, Carlos, Fernandez Vega, Alvaro, Ferrone, Philip, Figueira, Joao, Figueroa, Marta, Findl, Oliver, Fine, Howard, Fortun, Jorge, Fox, Gregory M., Foxman, Scott, Framme, Carsten, Fraser-Bell, Samantha, Fu, Arthur, Fukutomi, Akira, Fung, Nicholas, Furno Sola, Federico, Gallego-Pinazo, Roberto, Garcia, Renata, Garcia-Layana, Alfredo, Gawecki, Maciej, George, Sheen, Ghanchi, Faruque, Ghorayeb, Ghassan, Goldberg, Roger, Goldstein, Michaella, Gomes, Nuno, Ulla, Francisco Gomez, Gonzalez, Victor, Greven, Craig, Gupta, Sunil, Guzman, Miguel, Harris, Martin, Hatz, Katja, Hau, Vivienne, Hau, Vincent, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Hirakata, Akito, Ho, Allen, Holekamp, Nancy, Honda, Shigeru, Hsu, Jason, Hu, Allen, Hurcikova, Maria, Ikeda, Yasuhiro, Isernhagen, Ricky, Ito, Yasuki, Jackson, Tim, Jacoby, Rachael, Jafree, Afsar, Javey, Golnaz, Javid, Cameron, Jhaveri, Chirag, Johnson, Mark, Kacerík, Marek, Kaluzny, Jakub, Kampik, Daniel, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kerenyi, Agnes, Khanani, Arshad, Khurana, Rahul, Kim, Brian, Kimura, Kazuhiro, Kishino, Genichiro, Kitano, Shigehiko, Klein-Mascia, Kendra, Kokame, Gregg, Korobelnik, Jean Francois, Kulikov, Alexey, Kuriyan, Ajay, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Laird, Philip, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Laugesen, Caroline, Lavinsky, Daniel, Lebreton, Olivier, Lee, Seong, Levy, Jaime, Lipkova, Blandina, Liu, Mimi, Liu, Judy, Lohmann, Chris P., London, Nikolas, Lorenz, Katrin, Lotery, Andrew, Lozano Rechy, David, Lujan, Silvio, Ma, Patrick, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Malik, Khurram, Marcus, Dennis, Margherio, Alan, Mastropasqua, Leonardo, Maturi, Raj, McCabe, Frank, McKibbin, Martin, Mehta, Hemal, Menon, Geeta, Mentes, Jale, Michalska-Malecka, Katarzyna, Misheva, Aneta, Mitamura, Yoshinori, Mitchell, Paul, Modi, Yasha, Mohamed, Quresh, Montero, Javier, Moore, Jeffrey, Morales Canton, Virgilio, Morori-Katz, Haia, Morugova, Tatiana, Murakami, Tomoaki, Muzyka-Wozniak, Maria, Nardi, Marco, Nemcansky, Jan, Nester-Ostrowska, Kamila, Neto, Julio, Newell, Charles, Nicolo, Massimo, Nielsen, Jared, Noda, Kousuke, Obana, Akira, Ogata, Nahoko, Oh, Hideyasu, Oh, Kean, Ohr, Matthew, Oleksy, Piotr, Oliver, Scott, Olivier, Sebastien, Osher, James, Ozcalışkan, Sehnaz, Ozturk, Banu, Papp, Andras, Park, Kyu Hyung, Parke, D. Wilkin, Parravano, Maria Cristina, Patel, Sugat, Patel, Sunil, Pearce, Ian, Pearlman, Joel, Penha, Fernando, Perente, Irfan, Perkins, Stephen, Pertile, Grazia, Petkova, Iva, Peto, Tunde, Pieramici, Dante, Pollreisz, Andreas, Pongsachareonnont, Pear, Pozdeyeva, Nadezhda, Priglinger, Siegfried, Qureshi, Jawad, Raczynska, Dorota, Rajagopalan, Rajesh, Ramirez Estudillo, Juan, Raskauskas, Paul, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Ricci, Federico, Rofagha, Soraya, Romanczak, Dominika, Romanowska-Dixon, Bożena, Rosberger, Daniel, Rosenblatt, Irit, Rosenblatt, Brett, Ross, Adam, Ruamviboonsuk, Paisan, Ruiz Moreno, Jose Maria, Salomão, Gustavo, Sandhu, Sukhpal, Sandner, Dirk, Sararols, Laura, Sawada, Osamu, Schadlu, Ramin, Schlottmann, Patricio, Schuart, Claudia, Seitz, Berthold, Seres, András, Sermet, Figen, Shah, Sandeep, Shah, Ankur, Shah, Rohan, Sharma, Sumit, Sheidow, Thomas, Sheth, Veeral, Shimouchi, Akito, Shimura, Masahiko, Sikorski, Bartosz, Silva, Rufino, Singer, Michael, Singerman, Lawrence, Singh, Rishi, Souied, Eric, Spinak, David J., Spital, Georg, Steinle, Nathan, Stern, Jeffrey, Stoller, Glenn, Stoltz, Robert, Stone, Cameron, Stone, Amy, Suan, Eric, Sugimoto, Masahiko, Sugita, Iichiro, Sun, Jennifer, Sun, Xiaodong, Suner, Ivan, Szalczer, Lajos, Szecsko, Timea, Tabassian, Ali, Tadayoni, Ramin, Takagi, Hitoshi, Takayama, Kei, Taleb, Alexandre, Talks, James, Tan, Gavin, Tanabe, Teruyo, Taylor, Stanford, Thach, Allen, Thompson, John, Tlucek, Paul, Torti, Robert, Tosheva Guneva, Daniela, Toth-Molnar, Edit, Uchiyama, Eduardo, Vajas, Attila, Varma, Deepali, Varsanyi, Balazs, Vassileva, Petja, Vaz-Pereira, Sara, Veith, Miroslav, Vela, Jose Ignacio, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Vorum, Henrik, Weber, Pamela, Wecke, Thoalf, Wee, Raymond, Weger, Martin, Weishaar, Paul, Wells, John A., Wickremasinghe, Sanjeewa, Williams, Thomas Reginald, Williams, Thomas, Williams, Geoff, Wolf, Armin, Wolfe, Jeremy, Wong, James, Wong, David, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C., Wylęgała, Edward, Yang, Chang-Hao, Yasukawa, Tsutomu, Yates, Paul, Yilmaz, Gursel, Yiu, Glenn, Yoon, Young Hee, Yoreh, Barak, Yoshida, Shigeo, Yu, Hyeong Gon, Yu, Seung Young, Yurieva, Tatiana, Zacharias, Leandro, Zaczek Zakrzewska, Karolina, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Zheutlin, Jeffrey, Wong, Tien Y., Haskova, Zdenka, Asik, Kemal, Baumal, Caroline R., Csaky, Karl G., Ives, Jane A., Jaffe, Glenn J., Korobelnik, Jean-François, Lin, Hugh, Murata, Toshinori, Schlottmann, Patricio G., Seres, András I., Silverman, David, and Tang, Yannan

Published
2024
Full Text
View/download PDF

2. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Author

Aaberg, Thomas, Jr, Abbey, Ashkan, Abdulaeva, Elmira, Abengoechea, Santiago, Abraham, Prema, Ach, Thomas, Adams, Serrhel, Adan Civera, Alfredo, Adrean, Sean, Agostini, Hansjurgen, Alam, Suhail, Alezzandrini, Arturo, Alfaro, Virgil, Aliseda, Daniel, Almony, Arghavan, Amat, Pedro, Amini, Payam, Antoszyk, Andrew, Arias, Luis, Asaria, Riaz, Avila, Marcos, Awh, Carl C, Bafalluy, Joaquin, Baker, Carl, Bandello, Francesco, Barakat, Mark, Barraza, Karen, Bator, Gyorgy, Baumal, Caroline, Belfort Jr, Rubens, Bergstrom, Chris, Bertolucci, George, Bochow, Thomas, Bolz, Matthias, Borcz, Emilia, Bordon, Arnaldo, Boyer, David, Bratko, Galina, Brent, Michael, Brown, Jamin, Brown, David M, Budzinskaya, Maria, Buffet, Sylvia, Burgess, Stuart, Burton, Ben, Busquets, Miguel, Cabrera, Francisco, Cagini, Carlo, Calzada, Jorge, Campochiaro, Peter, Carlson, John, Castellarin, Alessandro, Cava, Carlos, Chaikitmongkol, Voraporn, Chan, Clement, Chang, Emmanuel, Chang, Jonathan, Chang, Andrew, Charles, Steve, Chaudhry, Nauman, Chee, Caroline, Chen, Judy, Chen, Fred, Chen, Shih-Jen, Cheong-Leen, Richard, Chiang, Allen, Chittum, Mark, Chow, David, Connolly, Brian, Cornut, Pierre Loic, Csaky, Karl, Danzig, Carl, Das, Arup, Daskalov, Vesselin, Desco, Carmen, Dessouki, Amr, Dickinson, John, Do, Brian, Dollin, Michael, Dugel, Pravin, Dusova, Jaroslava, Eichenbaum, David, Eldem, Bora, Engstrom, Robert, Ernest, Jan, Escobar, Joan Josep, Esposti, Simona, Eter, Nicole, Falk, Naomi, Farkas, Andrej, Feiner, Leonard, Feltgen, Nicolas, Fernandez, Carlos, Fernandez Vega, Alvaro, Ferrone, Philip, Figueira, Joao, Figueroa, Marta, Findl, .Oliver, Fine, Howard, Fortun, Jorge, Fox, Gregory M, Foxman, Scott, Framme, Carsten, Fraser-Bell, Samantha, Fu, Arthur, Fukutomi, Akira, Fung, Nicholas, Furno Sola, Federico, Gallego-Pinazo, Roberto, Garcia, Renata, Garcia-Layana, Alfredo, Gawecki, Maciej, George, Sheen, Ghanchi, Faruque, Ghorayeb, Ghassan, Goldberg, Roger, Goldstein, Michaella, Gomes, Nuno, Gomez Ulla, Francisco, Gonzalez, Victor, Greven, Craig, Gupta, Sunil, Guzman, Miguel, Harris, Martin, Hatz, Katja, Hau, Vivienne, Hau, Vincent, Hayashi, Ken, Heier, Jeffrey, Herba, Ewa, Hershberger, Vrinda, Higgins, Patrick, Hirakata, Akito, Ho, Allen, Holekamp, Nancy, Honda, Shigeru, Hsu, Jason, Hu, Allen, Hurcikova, Maria, Ikeda, Yasuhiro, Isernhagen, Ricky, Ito, Yasuki, Jackson, Tim, Jacoby, Rachael, Jafree, Afsar, Javey, Golnaz, Javid, Cameron, Jhaveri, Chirag, Johnson, Mark, Kacerík, Marek, Kaluzny, Jakub, Kampik, Daniel, Kang, Se Woong, Kapoor, Kapil, Karabas, Levent, Kawasaki, Tsutomu, Kerenyi, Agnes, Khanani, Arshad, Khurana, Rahul, Kim, Brian, Kimura, Kazuhiro, Kishino, Genichiro, Kitano, Shigehiko, Klein-Mascia, Kendra, Kokame, Gregg, Korobelnik, Jean Francois, Kulikov, Alexey, Kuriyan, Ajay, Kwong, Henry, Kwun, Robert, Lai, Timothy, Lai, Chi-Chun, Laird, Philip, Lalonde, Laurent, Lanzetta, Paolo, Larsen, Michael, Laugesen, Caroline, Lavinsky, Daniel, Lebreton, Olivier, Lee, Seong, Levy, Jaime, Lipkova, Blandina, Liu, Mimi, Liu, Judy, Lohmann, Chris P, London, Nikolas, Lorenz, Katrin, Lotery, Andrew, Lozano Rechy, David, Lujan, Silvio, Ma, Patrick, Maeno, Takatoshi, Mahmood, Sajjad, Makkouk, Fuad, Malik, Khurram, Marcus, Dennis, Margherio, Alan, Mastropasqua, Leonardo, Maturi, Raj, McCabe, Frank, McKibbin, Martin, Mehta, Hemal, Menon, Geeta, Mentes, Jale, Michalska-Malecka, Katarzyna, Misheva, Aneta, Mitamura, Yoshinori, Mitchell, Paul, Modi, Yasha, Mohamed, Quresh, Montero, Javier, Moore, Jeffrey, Morales Canton, Virgilio, Morori-Katz, Haia, Morugova, Tatiana, Murakami, Tomoaki, Muzyka-Wozniak, Maria, Nardi, Marco, Nemcansky, Jan, Nester-Ostrowska, Kamila, Neto, Julio, Newell, Charles, Nicolo, Massimo, Nielsen, Jared, Noda, Kousuke, Obana, Akira, Ogata, Nahoko, Oh, Hideyasu, Oh, Kean, Ohr, Matthew, Oleksy, Piotr, Oliver, Scott, Olivier, Sebastien, Osher, James, Ozcalişkan, Sehnaz, Ozturk, Banu, Papp, Andras, Park, Kyu Hyung, Parke, D Wilkin, Parravano, Maria Cristina, Patel, Sugat, Patel, Sunil, Pearce, Ian, Pearlman, Joel, Penha, Fernando, Perente, Irfan, Perkins, Stephen, Pertile, Grazia, Petkova, Iva, Peto, Tunde, Pieramici, Dante, Pollreisz, Andreas, Pongsachareonnont, Pear, Pozdeyeva, Nadezhda, Priglinger, Siegfried, Qureshi, Jawad, Raczynska, Dorota, Rajagopalan, Rajesh, Ramirez Estudillo, Juan, Raskauskas, Paul, Rathod, Rajiv, Razavi, Hessam, Regillo, Carl, Ricci, Federico, Rofagha, Soraya, Romanczak, Dominika, Romanowska-Dixon, Bożena, Rosberger, Daniel, Rosenblatt, Irit, Rosenblatt, Brett, Ross, Adam, Ruamviboonsuk, Paisan, Ruiz Moreno, Jose Maria, Salomão, Gustavo, Sandhu, Sukhpal, Sandner, Dirk, Sararols, Laura, Sawada, Osamu, Schadlu, Ramin, Schlottmann, Patricio, Schuart, Claudia, Seitz, Berthold, Seres, András, Sermet, Figen, Shah, Sandeep, Shah, Ankur, Shah, Rohan, Sharma, Sumit, Sheidow, Thomas, Sheth, Veeral, Shimouchi, Akito, Shimura, Masahiko, Sikorski, Bartosz, Silva, Rufino, Singer, Michael, Singerman, Lawrence, Singh, Rishi, Souied, Eric, Spinak, David J, Spital, Georg, Steinle, Nathan, Stern, Jeffrey, Stoller, Glenn, Stoltz, Robert, Stone, Cameron, Stone, Amy, Suan, Eric, Sugimoto, Masahiko, Sugita, Iichiro, Sun, Jennifer, Sun, Xiaodong, Suner, Ivan, Szalczer, Lajos, Szecsko, Timea, Tabassian, Ali, Tadayoni, Ramin, Takagi, Hitoshi, Takayama, Kei, Taleb, Alexandre, Talks, James, Tan, Gavin, Tanabe, Teruyo, Taylor, Stanford, Thach, Allen, Thompson, John, Tlucek, Paul, Torti, Robert, Tosheva Guneva, Daniela, Toth-Molnar, Edit, Uchiyama, Eduardo, Vajas, Attila, Varma, Deepali, Varsanyi, Balazs, Vassileva, Petja, Vaz-Pereira, Sara, Veith, Miroslav, Vela, Jose Ignacio, Viola, Francesco, Virgili, Gianni, Vogt, Gábor, Vorum, Henrik, Weber, Pamela, Wecke, Thoalf, Wee, Raymond, Weger, Martin, Weishaar, Paul, Wells, John A, Wickremasinghe, Sanjeewa, Williams, Thomas Reginald, Williams, Thomas, Williams, Geoff, Wolf, Armin, Wolfe, Jeremy, Wong, James, Wong, David, Wong, Ian, Wong, Robert, Wowra, Bogumil, Wykoff, Charles C, Wylęgała, Edward, Yang, Chang-Hao, Yasukawa, Tsutomu, Yates, Paul, Yilmaz, Gursel, Yiu, Glenn, Yoon, Young Hee, Yoreh, Barak, Yoshida, Shigeo, Yu, Hyeong Gon, Yu, Seung Young, Yurieva, Tatiana, Zacharias, Leandro, Zaczek Zakrzewska, Karolina, Zambrano, Alberto, Zatorska, Barbara, Zeolite, Carlos, Zheutlin, Jeffrey, Abreu, Francis, Adamis, Anthony P, Basu, Karen, Eichenbaum, David A, Haskova, Zdenka, Lin, Hugh, Loewenstein, Anat, Mohan, Shaun, Pearce, Ian A, Sakamoto, Taiji, Schlottmann, Patricio G, Silverman, David, Sun, Jennifer K, and Willis, Jeffrey R

Published
2022
Full Text
View/download PDF

13. Severe Eye Injuries in the War in Iraq, 2003–2005

Author

Thach, Allen B., Johnson, Anthony J., Carroll, Robert B., Huchun, Ava, Ainbinder, Darryl J., Stutzman, Richard D., Blaydon, Sean M., DeMartelaere, Sheri L., Mader, Thomas H., Slade, Clifton S., George, Roger K., Ritchey, John P., Barnes, Scott D., and Fannin, Lilia A.

Subjects
*WAR victims, *VETERANS with disabilities, *WAR
Abstract

Purpose: To document the incidence and treatment of patients with severe ocular and ocular adnexal injuries during Operation Iraqi Freedom. Design: Retrospective hospital-based observational analysis of injuries. Participants: All coalition forces, enemy prisoners of war, and civilians with severe ocular and ocular adnexal injuries. Methods: The authors retrospectively examined severe ocular and ocular adnexal injuries that were treated by United States Army ophthalmologists during the war in Iraq from March 2003 through December 2005. Main Outcome Measures: Incidence, causes, and treatment of severe ocular and ocular adnexal injuries. Results: During the time data were gathered, 797 severe eye injuries were treated. The most common cause of the eye injuries was explosions with fragmentation injury. Among those injured, there were 438 open globe injuries, of which 49 were bilateral. A total of 116 eyes were removed (enucleation, evisceration, or exenteration), of which 6 patients required bilateral enucleation. Injuries to other body systems were common. Conclusions: Severe eye injuries represent a significant form of trauma encountered in Operation Iraqi Freedom. These injuries were most commonly caused by explosion trauma. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

14. Feasibility of telerobotic microsurgical repair of corneal lacerations in an animal eye model.

Author

Mines, Michael J., Bower, Kraig S., Nelson, Brett, Ward, Thomas P., Belyea, David A., Kramer, Kenyon, and Thach, Allen B.

Subjects
MEDICAL technology, OPHTHALMIC surgery, MEDICAL telematics, TELEMEDICINE, DIGITAL computer simulation, MEDICINE
Abstract

We evaluated the feasibility of telerobotic microsurgical repair of corneal lacerations. The telerobotic microsurgical device consisted of a Robotic Slave Micromanipulator Unit (RSMU) coupled to a Telepresence Surgical System (TeSS). Five mm central full-thickness corneal wounds were fashioned in five enucleated rabbit eyes and repaired remotely using the telerobotic system. Five additional eyes were also repaired by hand using a standard technique. The primary outcome measure was creation of a watertight seal. All eyes in both groups maintained an intraocular pressure (IOP) of 25 mm Hg without leak. The mean repair time was 80 min (range 50–130) with telerobotic surgery compared to 8 min (range 7–9) by hand. Histological evaluation showed that suture placement was similar in robotically assisted repair and manual repair. Subjectively, the telerobotic system provided adequate three-dimensional visualization of the surgical field. The study showed that a surgeon could close standardized corneal wounds using the telerobotic system. The potential benefits of remote eye surgery include improved access, surgical teleconsultation and telementoring. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

15. Intraocular Foreign Body Injuries during Operation Iraqi Freedom

Author

Thach, Allen B., Ward, Thomas P., Dick, John S.B., Bauman, Wendall C., Madigan, William P., Goff, Mitchell J., and Thordsen, John E.

Subjects
*OPHTHALMIC surgery, *HEALTH outcome assessment, *VISUAL acuity, *CELL nuclei
Abstract

Objective: To evaluate the number of intraocular foreign body (IOFB) injuries that occurred in Operation Iraqi Freedom, and to determine the cause of injury, the type of foreign body, and the associated injuries to other body systems. Design: Retrospective, noncomparative, interventional case series. Participants: Fifty-five United States military personnel with an IOFB injury during Operation Iraqi Freedom. Intervention: Pars plana vitrectomy, foreign body removal, and additional surgical procedures as the clinical situation dictated. Main Outcome Measures: Cause of injury, size of corneal/scleral laceration, number of foreign bodies, type of foreign body, time to foreign body removal, visual acuity, number of enucleations, and injuries to other body systems. Results: The foreign body was caused by a propelled explosive in 20 patients (36%) and a nonpropelled explosive in 31 patients (56%), and the cause of the foreign body was not known in 4 patients (7%). The size of the laceration of the cornea and/or sclera averaged 5.4 mm (range, 0.2–18). There were an average of 1.7 foreign bodies in the injured eye (range, 1–6). The size of those foreign bodies measured ranged from <1 mm to 12 × 14 mm. The most common type of foreign body was metal (68%), followed by glass (14%), stone/cement (14%), bone (5%), and cilia (3%). The time from injury to foreign body removal averaged 20.6 days (range, 0–90). No cases of endophthalmitis were seen. The most common associated injury was to the upper extremity, face, lower extremity, and neck. Conclusions: Unlike trauma in the civilian sector, IOFB injuries in a military setting tend to be caused by explosive devices, which often result in multiple foreign bodies and simultaneous injuries to other body systems. Because of the lack of availability of specialty care in the combat theater, there is often a delay in removal of the foreign body. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

17. Time to Clinically Significant Visual Acuity Gains after Ranibizumab Treatment for Retinal Vein Occlusion BRAVO and CRUISE Trials

Author

Thach, Allen B., Yau, Linda, Hoang, Carol, and Tuomi, Lisa

Subjects
genetic structures
Abstract

PurposeTo assess time to first achievement of clinically significant visual acuity (VA) gains from baseline in patients with retinal vein occlusion (RVO) receiving ranibizumab versus sham treatment.DesignPost hoc analyses of 2 phase 3 clinical trials assessing efficacy and safety of ranibizumab in patients with branch RVO (Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety [BRAVO] study; NCT00061594) and central RVO (Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein Occlusion Study: Evaluation of Efficacy and Safety [CRUISE]; NCT00056836) over 12 months.ParticipantsSeven hundred eighty-nine patients (BRAVO, n = 397; CRUISE, n = 392).InterventionRandomization to monthly intraocular ranibizumab injections (0.3 mg/0.5 mg) or sham. After 6 monthly injections (treatment period), patients meeting prespecified criteria received as-needed (pro re nata [PRN]) ranibizumab at their assigned dose (sham patients, ranibizumab 0.5 mg) through month 12 (observation period). BRAVO patients meeting specific eligibility criteria could receive rescue laser treatment once during the treatment and once during the observation periods.Main Outcome MeasuresTime to first gain of 15 letters or more from baseline, analyzed using Kaplan-Meier methods. To evaluate the effect of delaying ranibizumab treatment, sham patients' VA data also were analyzed, with month 6 considered as baseline to assess vision gains during the 6 months of receiving ranibizumab PRN.ResultsMedian time to first 15-letter or more gain from baseline was 12.0 (sham), 4.8 (ranibizumab 0.3 mg), and 4.0 months (ranibizumab 0.5 mg) in BRAVO and 12.2, 5.9, and 5.2 months, respectively, in CRUISE. The cumulative proportion of patients who had ever gained 15 letters or more from baseline by month 12 was 50% (sham), 68% (ranibizumab 0.3 mg), and 71% (ranibizumab 0.5 mg) in BRAVO and 42%, 61%, and 66%, respectively, in CRUISE. After 6 months of ranibizumab PRN treatment, a cumulative 10.8% (BRAVO) and 26.2% (CRUISE) of initially sham-treated patients ever gained 15 letters or more.ConclusionsThis retrospective analysis shows that more than 50% of patients treated with monthly ranibizumab achieved clinically significant vision gains during the initial 6 months of treatment, which largely were maintained using PRN treatment to 12 months. In comparison, less than 50% of patients initially randomized to sham (and later receiving ranibizumab 0.5 mg PRN treatment) ever achieved clinically significant vision gains. These results suggest that initiating treatment immediately after diagnosis may provide the greatest vision gains. The potential benefits of early treatment should be evaluated further in prospective clinical studies.

Full Text
View/download PDF

26. Ophthalmic Care of the Combat Casualty (Book).

Author

Thach, Allen B. and Nolan, Brian T.

Subjects
*OPHTHALMOLOGY, *NONFICTION
Abstract

Reviews the book "Ophthalmic Care of the Combat Casualty," by Allen B. Thach.

Published
2004

28. Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

Author

Nguyen, Quan Dong, Shah, Syed Mahmood, Khwaja, Afsheen A., Channa, Roomasa, Hatef, Elham, Do, Diana V., Boyer, David, Heier, Jeffery S., Abraham, Prema, Thach, Allen B., Lit, Eugene S., Foster, Bradley S., Kruger, Erik, Dugel, Pravin, Chang, Thomas, Das, Arup, Ciulla, Thomas A., Pollack, John S., Lim, Jennifer I., and Eliot, Dean

Subjects
*METABOLIC disorder treatment, *EDEMA, *MONOCLONAL antibodies, *HEALTH outcome assessment, *PEOPLE with diabetes, *RANDOMIZED controlled trials, *LASER coagulation, *VISUAL acuity
Abstract

Objectives: To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME). Design: Prospective, randomized, interventional, multicenter clinical trial. Participants: One hundred twenty-six patients with DME. Methods: Subjects were randomized 1:1:1 to receive 0.5 mg RBZ at baseline and months 1, 3, and 5 (group 1), focal or grid laser photocoagulation at baseline and month 3 if needed (group 2), or a combination of 0.5 mg RBZ and focal or grid laser at baseline and month 3 (group 3). Starting at month 6, if retreatment criteria were met, all subjects could be treated with RBZ. Main Outcome Measures: The mean change from baseline in best-corrected visual acuity (BCVA) at month 24. Results: After the primary end point at month 6, most patients in all groups were treated only with RBZ, and the mean number of injections was 5.3, 4.4, and 2.9 during the 18-month follow-up period in groups 1, 2, and 3, respectively. For the 33 patients in group 1, 34 patients in group 2, and 34 patients in group 3 who remained in the study through 24 months, the mean improvement in BCVA was 7.4, 0.5, and 3.8 letters at the 6-month primary end point, compared with 7.7, 5.1, and 6.8 letters at month 24, and the percentage of patients who gained 3 lines or more of BCVA was 21, 0, and 6 at month 6, compared with 24, 18, and 26 at month 24. The percentage of patients with 20/40 or better Snellen equivalent at month 24 was 45% in group 1, 44% in group 2, and 35% in group 3. Mean foveal thickness (FTH), defined as center subfield thickness, at month 24 was 340 μm, 286 μm, and 258 μm for groups 1, 2, and 3, respectively, and the percentage of patients with center subfield thickness of 250 μm or less was 36%, 47%, and 68%, respectively. Conclusions: Intraocular injections of RBZ provided benefit for patients with DME for at least 2 years, and when combined with focal or grid laser treatments, the amount of residual edema was reduced, as were the frequency of injections needed to control edema. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

29. Authors' reply

Author

Dugel, Pravin U., Heuer, Dale K., Thach, Allen B., Baerveldt, George, Lee, Paul P., Lloyd, Mary Ann, Minckler, Don S., and Green, Ronald L.

Published
1997
Full Text
View/download PDF

30. Macular pucker removal with and without internal limiting membrane peeling: pilot study.

Author

Park, Donald W., Dugel, Pravin U., Garda, Jennifer, Sipperley, Jack O., Thach, Allen, Sneed, Scott R., and Blaisdell, Jennifer

Subjects
*RETINAL degeneration, *BIOLOGICAL membranes
Abstract

: ObjectiveTo investigate results of macular pucker surgery with and without internal limiting membrane (ILM) peeling.: DesignRetrospective noncomparative interventional case series.: ParticipantsForty-four consecutive patients underwent pars plana vitrectomy to remove an idiopathic macular pucker by two surgeons from June 1999 to July 2000.: InterventionDuring the vitrectomy, one surgeon removed only the macular epiretinal membrane (24 patients), whereas the other surgeon removed the macular epiretinal membrane and then performed an additional ILM peeling (20 patients).: Main outcome measuresVisual acuity and recurrence of macular pucker.: ResultsTwenty-four (55%) patients underwent pars plana vitrectomy without ILM peeling, and 20 patients (45%) underwent pars plana vitrectomy with ILM peeling. Visual acuity improved or was unchanged in 79% of operated eyes without ILM peeling and 100% of operated eyes with ILM peeling (P = 0.01). Visual acuity improved 5 or more lines in 25% of operated eyes without ILM peeling and 30% of operated eyes with ILM peeling. At the final visit, 21% of eyes without ILM peeling at the initial surgery showed postoperative recurrent macular pucker or persistent contraction to the ILM, whereas none of the eyes with ILM peeling had evidence of this.: ConclusionsThis pilot study provides evidence that peeling of the ILM during macular pucker surgery may not have deleterious effects. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

31. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.

Author

Thach AB, Yau L, Hoang C, and Tuomi L

Subjects
Adult, Aged, Female, Humans, Intravitreal Injections, Macular Edema diagnosis, Macular Edema physiopathology, Male, Middle Aged, Ranibizumab, Retinal Vein Occlusion diagnosis, Retinal Vein Occlusion physiopathology, Retreatment, Retrospective Studies, Time Factors, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A antagonists & inhibitors, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Macular Edema drug therapy, Retinal Vein Occlusion drug therapy, Visual Acuity physiology
Abstract

Purpose: To assess time to first achievement of clinically significant visual acuity (VA) gains from baseline in patients with retinal vein occlusion (RVO) receiving ranibizumab versus sham treatment., Design: Post hoc analyses of 2 phase 3 clinical trials assessing efficacy and safety of ranibizumab in patients with branch RVO (Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety [BRAVO] study; NCT00061594) and central RVO (Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein Occlusion Study: Evaluation of Efficacy and Safety [CRUISE]; NCT00056836) over 12 months., Participants: Seven hundred eighty-nine patients (BRAVO, n = 397; CRUISE, n = 392)., Intervention: Randomization to monthly intraocular ranibizumab injections (0.3 mg/0.5 mg) or sham. After 6 monthly injections (treatment period), patients meeting prespecified criteria received as-needed (pro re nata [PRN]) ranibizumab at their assigned dose (sham patients, ranibizumab 0.5 mg) through month 12 (observation period). BRAVO patients meeting specific eligibility criteria could receive rescue laser treatment once during the treatment and once during the observation periods., Main Outcome Measures: Time to first gain of 15 letters or more from baseline, analyzed using Kaplan-Meier methods. To evaluate the effect of delaying ranibizumab treatment, sham patients' VA data also were analyzed, with month 6 considered as baseline to assess vision gains during the 6 months of receiving ranibizumab PRN., Results: Median time to first 15-letter or more gain from baseline was 12.0 (sham), 4.8 (ranibizumab 0.3 mg), and 4.0 months (ranibizumab 0.5 mg) in BRAVO and 12.2, 5.9, and 5.2 months, respectively, in CRUISE. The cumulative proportion of patients who had ever gained 15 letters or more from baseline by month 12 was 50% (sham), 68% (ranibizumab 0.3 mg), and 71% (ranibizumab 0.5 mg) in BRAVO and 42%, 61%, and 66%, respectively, in CRUISE. After 6 months of ranibizumab PRN treatment, a cumulative 10.8% (BRAVO) and 26.2% (CRUISE) of initially sham-treated patients ever gained 15 letters or more., Conclusions: This retrospective analysis shows that more than 50% of patients treated with monthly ranibizumab achieved clinically significant vision gains during the initial 6 months of treatment, which largely were maintained using PRN treatment to 12 months. In comparison, less than 50% of patients initially randomized to sham (and later receiving ranibizumab 0.5 mg PRN treatment) ever achieved clinically significant vision gains. These results suggest that initiating treatment immediately after diagnosis may provide the greatest vision gains. The potential benefits of early treatment should be evaluated further in prospective clinical studies., (Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

32. Teleophthalmology in the evaluation of ocular trauma.

Author

Simon DP, Thach AB, and Bower KS

Subjects
Animals, Chi-Square Distribution, Diagnosis, Differential, Goats, Internet, Military Medicine, Eye Injuries diagnosis, Telemedicine
Abstract

Objective: The objective of this investigation is to evaluate the efficacy of teleophthalmology in the assessment of anterior segment and ocular adnexal trauma using digital imaging devices., Methods: Eight ocular injuries were created in an animal model. Two separate photographers of different skill levels photographed each injury using four different cameras. The images were transmitted via the Internet and were reviewed by 83 ophthalmologists masked as to the injury, camera, and photographer. The ability to make the correct diagnosis was evaluated., Results: The correct diagnoses were made most consistently for the full-thickness eyelid laceration (96%), corneoscleral laceration with uveal prolapse (92%), partial-thickness eyelid laceration (86%), and hyphema (80%). The correct diagnoses were made less frequently with the intraocular foreign body (10%), normal eye (39%), and corneal foreign body (46%)., Conclusions: With the current technology, it appears that teleophthalmology can be used with some reliability to assist with the diagnosis of certain ocular injuries. However, improvements in technology will be necessary before the diagnosis of most intraocular injuries will be able to be done on a consistent basis.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results